Is Bausch Health Companies Inc. (BHC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1043.9% / 30% | 65.5% / 30% | 117.7% / 30% | 0.47% / 5% | ✗ NOT HALAL |
| DJIM | 1043.9% / 33% | 65.5% / 33% | 117.7% / 33% | 0.47% / 5% | ✗ NOT HALAL |
| MSCI | 79.1% / 33% | 5.0% / 33% | 8.9% / 33% | 0.47% / 5% | ✗ NOT HALAL |
| S&P | 1043.9% / 33% | 65.5% / 33% | 117.7% / 33% | 0.47% / 5% | ✗ NOT HALAL |
| FTSE | 79.1% / 33% | 5.0% / 33% | 8.9% / 50% | 0.47% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 70.7% | |
| Operating Margin | 25.8% | |
| Net Margin | 1.5% | |
| Return on Equity (ROE) | 436.4% | |
| Return on Assets (ROA) | 5.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.4B |
| Free Cash Flow | $993M |
| Total Debt | $20.9B |
| Debt-to-Equity | 5591.2 |
| Current Ratio | 1.5 |
| Total Assets | $26.4B |
Price & Trading
| Last Close | $5.12 |
| 50-Day MA | $5.74 |
| 200-Day MA | $6.46 |
| Avg Volume | 2.2M |
| Beta | 0.4 |
|
52-Week Range
$4.25
| |
About Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Bausch Health Companies Inc. (BHC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Bausch Health Companies Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Bausch Health Companies Inc.'s debt ratio?
Bausch Health Companies Inc.'s debt ratio is 1043.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 79.1%.
What are Bausch Health Companies Inc.'s key financial metrics?
Bausch Health Companies Inc. has a market capitalization of $1.9B, trailing P/E ratio of 12.0, and revenue of $10.3B. The company maintains a gross margin of 70.7% and a net margin of 1.5%. Return on equity stands at 436.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.